WO2006074182A3 - Mobilisation par therapie au facteur de croissance de cellules souches dans le sang peripherique - Google Patents

Mobilisation par therapie au facteur de croissance de cellules souches dans le sang peripherique Download PDF

Info

Publication number
WO2006074182A3
WO2006074182A3 PCT/US2006/000115 US2006000115W WO2006074182A3 WO 2006074182 A3 WO2006074182 A3 WO 2006074182A3 US 2006000115 W US2006000115 W US 2006000115W WO 2006074182 A3 WO2006074182 A3 WO 2006074182A3
Authority
WO
WIPO (PCT)
Prior art keywords
stem cells
peripheral blood
mobilization
growth factor
vegf
Prior art date
Application number
PCT/US2006/000115
Other languages
English (en)
Other versions
WO2006074182A2 (fr
Original Assignee
Franco Wayme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/029,449 external-priority patent/US7291597B2/en
Application filed by Franco Wayme filed Critical Franco Wayme
Priority to EP06717336A priority Critical patent/EP1841462A4/fr
Publication of WO2006074182A2 publication Critical patent/WO2006074182A2/fr
Publication of WO2006074182A3 publication Critical patent/WO2006074182A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/04—Uses of viruses as vector in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Selon l'invention, des cellules souches sont mobilisées dans le sang périphérique au moyen d'une méthode consistant (i) à administrer à un individu l'un au moins de FGF1 et FGF2 et l'un au moins de VEGF, VEGFA et VEGF165, (ii) à isoler les cellules souches du sang périphérique (PBSC) par aphérèse, et (iii) à injecter les PBSC dans le corps d'un patient souffrant d'une maladie cardiaque chronique. Selon une autre variante, une thérapie génique est utilisée pour l'induction de cellules souches dans le sang périphérique, la préparation pour cette thérapie génique renfermant de l'ADN plasmidique VEGF165 ou AD5FGF-4. En outre, l'évolution du traitement de la maladie cardiaque chronique est surveillée au moyen d'une unité échocardiogramme.
PCT/US2006/000115 2005-01-05 2006-01-04 Mobilisation par therapie au facteur de croissance de cellules souches dans le sang peripherique WO2006074182A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06717336A EP1841462A4 (fr) 2005-01-05 2006-01-04 Mobilisation par therapie au facteur de croissance de cellules souches dans le sang peripherique

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/029,449 US7291597B2 (en) 2000-04-06 2005-01-05 Growth factor therapy mobilization of stem cells into the peripheral blood
US11/029,449 2005-01-05
US11/179,271 US7288521B2 (en) 2000-04-06 2005-07-12 Growth factor therapy mobilization of stem cells into the peripheral blood
US11/179,271 2005-07-12

Publications (2)

Publication Number Publication Date
WO2006074182A2 WO2006074182A2 (fr) 2006-07-13
WO2006074182A3 true WO2006074182A3 (fr) 2007-09-13

Family

ID=36648118

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/000115 WO2006074182A2 (fr) 2005-01-05 2006-01-04 Mobilisation par therapie au facteur de croissance de cellules souches dans le sang peripherique

Country Status (3)

Country Link
US (1) US7288521B2 (fr)
EP (1) EP1841462A4 (fr)
WO (1) WO2006074182A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090299269A1 (en) * 2008-05-29 2009-12-03 John Foley Vascular stimulation to aid intravascular cell replacement therapy
US8761860B2 (en) 2009-10-14 2014-06-24 Nocimed, Llc MR spectroscopy system and method for diagnosing painful and non-painful intervertebral discs
US8825131B2 (en) 2009-10-14 2014-09-02 Nocimed, Llc MR spectroscopy system and method for diagnosing painful and non-painful intervertebral discs
US9280718B2 (en) 2010-11-24 2016-03-08 Nocimed, Llc Systems and methods for automated voxelation of regions of interest for magnetic resonance spectroscopy
US8965094B2 (en) 2012-04-14 2015-02-24 Nocimed, Llc Magnetic resonance spectroscopy pulse sequence, acquisition, and processing system and method
RU2542385C2 (ru) 2012-08-31 2015-02-20 Общество с ограниченной ответственностью "НекстГен" Способ получения фармацевтической композиции для индукции развития кровеносных сосудов в тканях, фармацевтическая композиция, полученная этим способом, и способ лечения ишемии тканей и/или органов человека
RU2612497C2 (ru) 2015-05-26 2017-03-09 Общество с ограниченной ответственностью "НекстГен" Оптимизированная нуклеотидная последовательность и фармацевтическая композиция на ее основе с пролонгированной экспрессией трансгена vegf
US10631840B2 (en) 2015-11-25 2020-04-28 Talon Medical, LLC Tissue engagement devices, systems, and methods
EP4289347A3 (fr) 2016-06-19 2024-03-06 Aclarion, Inc. Système de spectroscopie par résonance magnétique et procédé de diagnostic de la douleur ou de l'infection associé à l'acide propionique
BR112021026832A2 (pt) 2019-07-02 2022-05-10 Hutchinson Fred Cancer Res Vetores ad35 recombinantes e aprimoramentos da terapia gênica relacionada
JP2022551911A (ja) * 2019-10-09 2022-12-14 キシロコル セラピューティクス インコーポレイテッド 遺伝子治療の心外膜送達
WO2023150393A2 (fr) 2022-02-07 2023-08-10 Ensoma, Inc. Modifications de mgmt résistante aux inhibiteurs et modification d'acides nucléiques codant mgmt

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030023995A1 (en) * 2002-09-06 2003-01-30 Robert Benezra Inhibitor of differentiation knockout mammals and methods of use thereof
US20040018174A1 (en) * 2002-07-23 2004-01-29 Boston Scientific Corporation Cell therapy for regeneration
US6759386B2 (en) * 2000-04-06 2004-07-06 Wayne P. Franco Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608182B1 (en) * 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US5932540A (en) * 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6734285B2 (en) * 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
DK1632574T3 (da) * 1996-10-16 2011-02-28 Zymogenetics Inc Fibroblast-vækstfaktor homologer
US20030103951A1 (en) 1997-07-14 2003-06-05 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US6775574B1 (en) * 1997-11-07 2004-08-10 Medtronic, Inc. Method and system for myocardial infarction repair
EP1060242A4 (fr) * 1998-01-23 2003-09-17 Imclone Systems Inc Populations purifiees de cellules souches
US6482406B1 (en) * 1999-03-26 2002-11-19 Duncan J. Stewart Cell-based gene therapy for the pulmonary system
US20030211994A1 (en) 1998-09-30 2003-11-13 Ludwig Institute For Cancer Research Composition and method for modulating vasculogenesis or angiogenesis
JP2003505475A (ja) * 1999-07-23 2003-02-12 ダイアクリン インク 筋細胞、及び心臓修復におけるそれらの利用
AU7611500A (en) 1999-09-24 2001-04-24 Abt Holding Company Pluripotent embryonic-like stem cells, compositions, methods and uses thereof
US6716626B1 (en) * 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
US20020142457A1 (en) 1999-12-28 2002-10-03 Akihiro Umezawa Cell having the potentiality of differentiation into cardiomyocytes
DE60140051D1 (de) * 2000-06-07 2009-11-12 Merck Serono Sa Coinsins Menschliches wachstumshormon zur stimulierung der mobilisierung pluripotenter hämapoietischer stammzellen
AU6842001A (en) 2000-06-15 2001-12-24 Tanja Dominko Pluripotent mammalian cells
US20040071665A1 (en) 2000-09-05 2004-04-15 Yong-Fu Xiao Method for therapeutically treating a clinically recognized form of cardiopathology in a living mammal
US20020172663A1 (en) 2001-01-23 2002-11-21 Maria Palasis Localized myocardial injection method for treating ischemic myocardium
KR101073411B1 (ko) 2001-07-12 2011-10-17 제론 코포레이션 인간 다분화능 줄기 세포로부터 제조된 심근 세포 계통의 세포
WO2003014326A2 (fr) * 2001-08-10 2003-02-20 Imclone Systems Incorporated Isolation et mobilisation de cellules souches exprimant vegfr-1
US20040048375A1 (en) 2001-09-30 2004-03-11 Scicotec Gmbh Application of pluripotential stem cells for body organ tissue repair and venous capillary expansion
US20030082148A1 (en) * 2001-10-31 2003-05-01 Florian Ludwig Methods and device compositions for the recruitment of cells to blood contacting surfaces in vivo
EP1459759A4 (fr) * 2001-11-19 2007-08-29 Kyowa Hakko Kogyo Kk Medicament mobilisant les cellules souches totipotentes d'un tissu dans le sang peripherique
JP4623967B2 (ja) 2002-01-14 2011-02-02 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 幹細胞の移動および増殖を促進するための修飾されたピリミジン化合物の使用
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US20040071687A1 (en) 2002-05-28 2004-04-15 Shahin Rafii Adult stem cell recruitment
US7628988B2 (en) 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
US7470538B2 (en) * 2002-12-05 2008-12-30 Case Western Reserve University Cell-based therapies for ischemia

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759386B2 (en) * 2000-04-06 2004-07-06 Wayne P. Franco Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease
US20040018174A1 (en) * 2002-07-23 2004-01-29 Boston Scientific Corporation Cell therapy for regeneration
US20030023995A1 (en) * 2002-09-06 2003-01-30 Robert Benezra Inhibitor of differentiation knockout mammals and methods of use thereof

Also Published As

Publication number Publication date
EP1841462A2 (fr) 2007-10-10
EP1841462A4 (fr) 2009-12-23
WO2006074182A2 (fr) 2006-07-13
US20050271634A1 (en) 2005-12-08
US7288521B2 (en) 2007-10-30

Similar Documents

Publication Publication Date Title
WO2006074182A3 (fr) Mobilisation par therapie au facteur de croissance de cellules souches dans le sang peripherique
WO2007117509A3 (fr) Vitesses d'administration élevées pour préparations médicamenteuses lipidiques et méthodes de traitement associées
WO2005072057A3 (fr) Oligoribonucleotides et procedes d'utilisation de ceux-ci dans le traitement d'etats fibreux et d'autres maladies
WO2006127007A3 (fr) Procedes d'utilisation de cellules derivees de tissus adipeux dans le traitement de maladies cardiovasculaires
WO2007029249A3 (fr) Oligoribonucleotides et leurs methodes d'utilisation dans le traitement des maladies cardio-vasculaires
WO2006089340A3 (fr) Administration d'un polynucleotide a un tissu cardiaque
WO2008006118A3 (fr) Nouveaux schémas posologiques destinés au traitement de maladies et de troubles
WO2006035434A3 (fr) Oligoribonucleotides et procedes d'utilisation associes pour le traitement de l'alopecie, des insuffisances renales aigues et d'autres maladies
WO2008052770A3 (fr) Arn à base modifiée utilisé pour accroître l'expression d'une protéine
WO2005123183A3 (fr) Dispositif d'electroporation et procede d'introduction d'adn dans les tissus oculaires
WO2004074457A3 (fr) Methodes d'utilisation de cellules derives de tissus adipeux dans le traitement d'etats cardiovasculaires
WO2006015214A3 (fr) Composition de cellules souches de cordon ombilical et methode de traitement de maladies neurologiques
WO2010033915A9 (fr) Méthode de régulation des taux sanguins de sucre, d'insuline, de cholestérol, des taux de graisse dans le corps, et du poids corporel par administration d'une matrice de fibres nutritives
WO2005001080A3 (fr) Cellules derivees de tissus post-partum destinees a etre utilisees pour traiter des maladies du coeur et du systeme circulatoire
WO2008070672A3 (fr) Compositions et procédés pour le traitement du cancer avec des cuprédoxines et de l'adn riche en cpg
WO2008066776A3 (fr) Procédés pour traiter l'hypercholestérolémie
WO2005000245A3 (fr) Compositions et methodes destinees a augmenter l'activite de la telomerase
WO2006014159A3 (fr) Methodes d'utilisation de cellules de regeneration dans le traitement de troubles musculo-squelettiques
WO2005037211A3 (fr) Methodes et compositions pour le traitement de maladies neurologiques
MX2009007723A (es) Medicacion basada en exenatida y dalargina para el tratamiento de diabetes mellitus, su uso y modalidad de tratamiento.
WO2006022612A3 (fr) Methodes d'utilisation de cellules regeneratrices dans le traitement d'accident vasculaire cerebral et de maladies et de troubles lies
WO2006016351A3 (fr) Distribution de medicament dans le sinus coronaire
WO2001005437A3 (fr) Methodes de traitement de maladies hyperproliferatives, au moyen de la proteine humaine mda-7
WO2006092795A3 (fr) Oligoribonucleotides et methodes permettant de les utiliser pour traiter la cicatrisation oculaire ainsi que d'autres fibroses
WO2006131925A3 (fr) Oligoribonucleotides et leurs procedes d'utilisation pour le traitement de conditions fibrotiques et d'autres maladies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006717336

Country of ref document: EP